Published in J Otol on January 01, 2013
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 17.38
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science (2004) 7.29
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem (2006) 3.18
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res (2002) 2.49
Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int (2006) 2.44
Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci U S A (2009) 2.33
Biochemical characterization of the human copper transporter Ctr1. J Biol Chem (2001) 2.28
Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci (2006) 1.89
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol (2005) 1.73
Multi-site diagnosis and management of 260 patients with auditory neuropathy/dys-synchrony (auditory neuropathy spectrum disorder). Int J Audiol (2010) 1.70
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol (2005) 1.61
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology (2006) 1.56
Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol (2002) 1.50
Clinical and audiological features in auditory neuropathy. Arch Otolaryngol Head Neck Surg (2002) 1.47
Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett (2004) 1.38
Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett (2005) 1.35
Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer (2001) 1.33
Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci (2000) 1.31
Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci (2006) 1.31
Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol (2007) 1.30
Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience (2003) 1.29
Cytotoxic effects of dimethyl sulphoxide (DMSO) on cochlear organotypic cultures. Hear Res (2007) 1.21
Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol (2007) 1.21
Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci (1998) 1.17
Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Am J Hum Genet (1999) 1.17
Drug antioxidant effects. A basis for drug selection? Drugs (1991) 1.16
Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol (1997) 1.16
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol (1996) 1.13
Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann N Y Acad Sci (1999) 1.13
SIR2 family of NAD(+)-dependent protein deacetylases. Methods Enzymol (2002) 1.09
Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology (2003) 1.08
Use of platinum derivatives during pregnancy. Cancer (2008) 1.08
Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol (2003) 1.06
Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice. Curr Gerontol Geriatr Res (2008) 1.06
Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J Am Chem Soc (2010) 1.05
A novel model for rapid induction of apoptosis in spiral ganglions of mice. Laryngoscope (2003) 1.05
Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol (2001) 1.05
New platinum antitumor complexes. Crit Rev Oncol Hematol (1993) 1.04
Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport (1998) 1.02
Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res (2002) 1.02
Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol (2004) 1.01
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer (2001) 1.00
Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res (2007) 1.00
Salicylate-induced degeneration of cochlea spiral ganglion neurons-apoptosis signaling. Neuroscience (2010) 0.96
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol (2001) 0.96
Clinical pharmacokinetics and administration of established platinum drugs. Drugs (2000) 0.94
Vitamin E reduces cisplatin ototoxicity. Laryngoscope (2004) 0.93
Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra. Neurochem Res (2003) 0.93
Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) (2012) 0.91
Aminoguanidine reduces cisplatin ototoxicity. Hear Res (2003) 0.91
Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res (2011) 0.90
Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL J Otorhinolaryngol Relat Spec (2004) 0.90
Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol (2004) 0.89
Poly(ADP-ribose) polymerase-1 protects neurons against apoptosis induced by oxidative stress. Cell Death Differ (2007) 0.85
Carboplatin versus cisplatin in ovarian cancer. Semin Oncol (1995) 0.84
Manganese is toxic to spiral ganglion neurons and hair cells in vitro. Neurotoxicology (2010) 0.84
[Cochleogram for assessing hair cells and efferent fibers in carboplatin-treated ear]. Lin Chuang Er Bi Yan Hou Ke Za Zhi (1999) 0.83
Regulation of ceruloplasmin in human hepatic cells by redox active copper: identification of a novel AP-1 site in the ceruloplasmin gene. Biochem J (2007) 0.83
Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. Auris Nasus Larynx (2003) 0.83
Early damage in the chinchilla vestibular sensory epithelium from carboplatin. Audiol Neurootol (1998) 0.82
Apoptosis and oxidative stress in the aging brain. Ann N Y Acad Sci (1996) 0.82
Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis (2008) 0.82
Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs (2000) 0.81
Sesame oil attenuates Cisplatin-induced hepatic and renal injuries by inhibiting nitric oxide-associated lipid peroxidation in mice. Shock (2007) 0.81
Scavenging activity of indole compounds against cisplatin-induced reactive oxygen species. Life Sci (2006) 0.79
Antioxidant and protective effects of Amrit Nectar tablets on adriamycin- and cisplatin-induced toxicities. J Altern Complement Med (2005) 0.78
Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol (2009) 0.78
OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATS. J Otol (2012) 0.77
Phase II study of carboplatin and cyclophosphamide combination chemotherapy for the treatment of advanced ovarian cancer. Eur J Gynaecol Oncol (1990) 0.76
[Cisplatin-induced apoptotic cell death in spiral ganglion and organ of Corti of mongolian gerbil cochlear]. Zhonghua Er Bi Yan Hou Ke Za Zhi (2003) 0.76
[About side effects of platinum drugs]. Postepy Hig Med Dosw (2001) 0.76
[Quantitation of nerve fibers in habenula perforata in chinchilla]. Zhonghua Er Bi Yan Hou Ke Za Zhi (1998) 0.76
Free radical scavengers suppress the accumulation of platinum in the cerebral cortex. Biol Trace Elem Res (1997) 0.76
Apoptosis and DNA fragmentation as induced by tertiary butylhydroperoxide in the brain. Brain Res Bull (1995) 0.76
Cisplatin as a cornerstone of modern chemotherapy. Lancet Oncol (2009) 0.76
Cisplatin and carboplatin induced changes in the neurohypophysis and parathyroid, and their role in nephrotoxicity. Anticancer Drugs (1993) 0.75